Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Sabina AndreuCentro de Biología Molecular "Severo Ochoa, " Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, c/ Nicolás Cabrera 1, Campus de Cantoblanco-UAM, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0003-0600-4152
Kai TangDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.ORCID https://orcid.org/0000-0002-9770-9459
Jiahui ZhouDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.
Gabriel Pino-PecoCentro de Biología Molecular "Severo Ochoa, " Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, c/ Nicolás Cabrera 1, Campus de Cantoblanco-UAM, Madrid, 28049, Spain.
Nerea López-CarroblesCentro de Biología Molecular "Severo Ochoa, " Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, c/ Nicolás Cabrera 1, Campus de Cantoblanco-UAM, Madrid, 28049, Spain.
Raquel Bello-MoralesDepartment of Molecular Biology, Universidad Autónoma de Madrid, c/ Darwin, 2 Cantoblanco, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0002-4415-6483
Daniel Galdo-TorresDepartment of Molecular Biology, Universidad Autónoma de Madrid, c/ Darwin, 2 Cantoblanco, Madrid, 28049, Spain.ORCID https://orcid.org/0009-0006-3532-4760
Lina ZhangDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.
José Antonio López-GuerreroCentro de Biología Molecular "Severo Ochoa, " Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, c/ Nicolás Cabrera 1, Campus de Cantoblanco-UAM, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0003-2817-5956
Xinyong LiuDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.ORCID https://orcid.org/0000-0002-7302-2214
Peng ZhanDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, P. R. China.ORCID https://orcid.org/0000-0002-9675-6026
Luis Menéndez-AriasCentro de Biología Molecular "Severo Ochoa, " Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, c/ Nicolás Cabrera 1, Campus de Cantoblanco-UAM, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0002-1251-6640
Funding
Key Technologies Research and Development Program 2023YFC2606500Ministerio de Ciencia, Innovación y Universidades PID2022-136307OB-C22/AEI/10.13039/501100011033Ministry of Science, Innovation and Universities of Spain PID2022Ministry of Science, Innovation and Universities of Spain PID2022-136725OB-I00/AEI/10.13039/501100011033Ministry of Science, Innovation and Universities of Spain PID2022-140632NB-I00/AEI/10.13039/501100011033Natural Science Foundation of Shandong Province ZR2024QH201Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation 2023M742101Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation GZC20231489Shandong Laboratory Program SYS202205
6 · The paper itself
Abstract
Herpes simplex viruses (HSV-1 and HSV-2) are highly prevalent and contagious, causing lifelong infections that cannot be eradicated with current therapies. Acyclovir and other viral DNA polymerase inhibitors are effective antiviral agents for treating HSV infections. However, despite the recent approval of pritelivir and amenamevir (helicase-primase complex inhibitors), drug resistance is still a major threat to therapeutic success. This research focuses on developing new antiviral strategies against HSV-1 by targeting the pUL15 endonuclease, a component of the viral packaging motor/terminase complex, using substituted polycyclic pyridones derived from baloxavir acid. Several compounds display low micromolar IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of a Baloxavir-Inspired Endonuclease Inhibitor That Prevents Herpes Simplex Virus 1 Replication in Cell Culture and In Vivo. · full record | OpenQuestion